AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.

AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentially outperforming existing therapies like Merck's Keytruda. AstraZeneca plans to combine ivonescimab with its antibody-drug conjugates to enhance cancer treatment options. The investment grants AstraZeneca a 12% stake in Summit but allows Summit to retain full commercial rights. Additionally, AstraZeneca opened a $1 billion R&D facility in Cambridge, Massachusetts, focused on accelerating drug discovery with AI and robotics.

As of Oct 06, 2026 03:02 WIB, AstraZeneca (AZN) trades near its 52-week low at USD 157.01, down 0.44% for the day, while Summit Therapeutics (SMMT) is up 2.92% at USD 17.25, closer to its 52-week low of USD 12.43 than its high of USD 26.38. Despite AstraZeneca's large market cap of $242.94 billion compared to Summit's $13.49 billion, Summit sees a much shorter typical hold time on Pluang (17 days vs. 126 days) and full buy order activity, reflecting different investor engagement levels as of the same timestamp.